A Look Into Healthcare Sector Value Stocks
Portfolio Pulse from Benzinga Insights
Benzinga Insights has identified five value stocks in the healthcare sector that may be worth watching: Leafly Holdings, Voyager Therapeutics, Viatris, Dynavax Technologies, and Histogen. These companies have low price-to-earnings (P/E) multiples, indicating potential undervaluation. However, the risk with value stocks is that they may not rebound from their undervalued position.
July 17, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Dynavax Technologies is identified as a potential value stock with a P/E of 8.92. However, its Q1 earnings per share decreased from 0.45 in Q4 to -0.19 now.
While Dynavax Technologies' low P/E multiple suggests potential undervaluation, its decreased earnings per share could be a concern for investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Histogen is identified as a potential value stock with a P/E of 0.69. However, its Q1 earnings per share decreased from -0.61 in Q4 to -0.81 now.
While Histogen's low P/E multiple suggests potential undervaluation, its decreased earnings per share could be a concern for investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Leafly Holdings is identified as a potential value stock with a P/E of 0.64. Its Q1 earnings per share increased by 17.65% compared to Q4.
Leafly Holdings' low P/E multiple and increased earnings per share suggest potential undervaluation and positive financial performance, which could attract investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Viatris is identified as a potential value stock with a P/E of 6.47. Its Q1 earnings per share increased from 0.67 in Q4 to 0.77 now, and its dividend yield increased to 5.32%.
Viatris' low P/E multiple, increased earnings per share, and increased dividend yield suggest potential undervaluation and positive financial performance, which could attract investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Voyager Therapeutics is identified as a potential value stock with a P/E of 4.15. Its earnings per share increased significantly from -0.61 in Q4 to $2.94 now.
Voyager Therapeutics' low P/E multiple and significant increase in earnings per share suggest potential undervaluation and strong financial performance, which could attract investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100